



HIV in Europe

Reducing barriers to HIV testing – what influences testing offer and uptake?

Lessons learned from the HIV in Europe Initiative

2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care

Dorthe Raben, Copenhagen HIV Programme on behalf of the HIV in Europe Initiative

Late diagnosis in Europe

- Of the estimated 2.5 million PLHIV in the European Region, 1 in 3 remain undiagnosed
- Over 50% of individuals are late presenters (LP) ($CD4 < 350$)
- The proportion of newly diagnosed persons who are LP decreased by 4% per year since 2000
- Considerable variation within different exposure groups and regions of Europe
- A substantial number of 'low risk' individuals continue to be LP

Health Policy in Europe

“defining national health policies remains an exclusive competence belonging to Member States. EU action shall not include the definition of health policies, nor the organisation and provision of health services and medical care.

European health policy therefore consists of developing a shared competence with Member States and complementing national policies.”

- Large variations in HIV testing recommendations – only a few countries have a policy of normalisation of HIV testing
- Large variations in access to prevention, testing, care and treatment

The HIV in Europe Initiative - Objectives

- Pan-European initiative

Aim

- **Ensure that HIV patients enter care earlier in the course of their infection** and study the decrease in the proportion of PLHIV presenting late for care

How?

- Providing a platform for activities aiming to increase early diagnosis and care for people living with HIV across Europe
- Network of stakeholders – exchange of best practices
Representation from patient advocacy, policy makers, health professionals and European public health institutions (ECDC, WHO Europe, EMCDDA, Global Fund, CDC)
- Through collaborative projects, conferences and advocacy, barriers to testing on provider, client and administrative levels are investigated.

The people living with HIV Stigma Index implications for testing uptake

HIV-related **Stigma:**

A cross analysis of findings
from the People Living
with HIV Stigma Index in
Estonia, Moldova, Poland,
Turkey, and Ukraine

**Late Testing,
Late Treatment**

The stigma index study concluded that fear of stigmatisation and criminalisation could delay uptake of both testing and care.

Phase II "From evidence to Action" (2012-2013):
Development of advocacy and actions in Estonia, Moldova, Poland, Turkey, Ukraine and Belarus.

HIV Indicator Conditions Guided HIV Testing – increasing testing offer rates

- The strategy to increase HIV testing through indicator condition guided HIV testing is feasible and (cost)-effective.
- Among 3588 individuals in 17 clinics routinely offered testing in 14 countries, eight indicator conditions associated with HIV were investigated and demonstrated an HIV prevalence of 1.8% (> 0.1%, a level determined to be cost-effective.)
- Healthcare professional related barriers: time limitations, perception of HIV as exceptional in regard to consent process, and lack of training.
- HIDES 1 (2009-2011): to be published in PLoS ONE
- HIDES 2 (2012-2013): screening of 14000 persons with 11 predefined indicator conditions


Guidance on Indicator Condition Guided HIV Testing

Target groups:

- European and national medical clinical societies
- European and National Policy Organisations
- Health Care Professionals

Strategy:

- Encourage publications in medical journals
- presentations at medical conferences in specialties other than infectious diseases
- Inclusion in guidelines and trainings



Some Conclusions

- Indicator condition guided HIV testing is a feasible and effective strategy to reduce the level of undiagnosed HIV infection in Europe.
- Expanding HIV testing in health care settings requires training – including on stigma as a barrier to testing.
- Political support on the national and European levels as well as auditing, monitoring and evaluation for impact is key.
- The results of the research are a good basis for advocacy across Europe.

The HIV in Europe SC and Study Groups



HIV in Europe Steering Committee: Co-Chairs: Ton Coenen, AIDS Action Europe, Executive Director Aids Fonds & Soa Aids Nederland, Netherlands and Jens Lundgren, Professor & Chief Physician, University of Copenhagen & Rigshospitalet, Director, Copenhagen HIV Programme, Denmark, Members: Jordi Casabona, Scientific Director, Center for HIV/STI Epidemiological Studies of Catalonia Nikos Dedes, European AIDS Treatment Group (EATG), Greece, Valerie Delpech, Health Protection Agency, London, United Kingdom, José Gatell, Head, Infectious Diseases & AIDS Units, Clinical Institute of Medicine & Dermatology, Hospital Clinic, Professor of Medicine, University of Barcelona, Spain, Brian Gazzard, Professor of Medicine, Imperial College School of Medicine, HIV Research Director, Chelsea & Westminster Hospital, UK, Igor Karpov, Professor, Department of Infectious Diseases, Belarus State Medical University, Jürgen Rockstroh, Professor of Medicine University of Bonn and Head of an HIV outpatient clinic, Germany, Anders Sönnberg, MD, PhD, Professor, Department of Medicine Karolinska University Hospital, Sweden, Nino Tsereteli, Executive Director of “Center for Information and Counseling on Reproductive Health – Tanadgoma”, John de Wit, Professor and Director, National Centre in HIV Social Research, The University of New South Wales, and Visiting Professor of Social Psychology of Health and Sexuality, Utrecht University, Observers: WHO Regional Office for Europe, STI/HIV/AIDS Programme, Represented by Lali Kotenashvili, European Centre for Disease Prevention and Control (ECDC), Represented by Marita van de Laar, PhD, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Represented by Lucas Wiessing, epidemiologist, principal scientist, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Represented by Vitaly Zhumagliev, Centers for Disease Control and Prevention (CDC), Represented by Kevin Fenton, UNAIDS Regional Support Team ECA, Represented by Jean-Elie Malkin.

European Late Presenter Consensus working group: A Antinori, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy, T Coenen, Aids Fonds & Soa Aids Nederland, Amsterdam, the Netherlands, D Costagiola, INSERM, Paris, France, N Dedes, European AIDS Treatment Group, Brussels, Belgium, M Ellefson, National University Hospital and Univ. of Copenhagen, Copenhagen HIV Programme, Panum Institute, Denmark, J Gatell, Clinical Institute of Medicine & Dermatology, Hospital Clinic, University of Barcelona, Barcelona, Spain, E Girardi, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy, M Johnson, Royal Free Hampstead NHS Trust, London, UK, O Kirk, National University Hospital and Univ. of Copenhagen, Copenhagen HIV Programme, Panum Institute, Denmark, J Lundgren, National University Hospital and Univ. of Copenhagen, Copenhagen HIV Programme, Panum Institute, Denmark, A Mocroft, University College London Medical School, Royal Free Campus, London, UK, A d’Arminio Monforte, Department of Medicine, San Paolo Hospital, Milan, Italy, A Phillips, University College London Medical School, Royal Free Campus, London, UK, D Raben, National University Hospital and Univ. of Copenhagen, Copenhagen HIV Programme, Panum Institute, Denmark, J K Rockstroh, Medizinischen Universitätsklinik, Innere-Rheuma-Tropen Ambulanz, Bonn, Germany, C Sabin, University College London Medical School, Royal Free Campus, London, UK, A Sönnberg, Department of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden, F de Wolf, HIV Monitoring Foundation, Amsterdam, the Netherlands.

Working Group on Estimation of HIV Prevalence in Europe (conveners: Andrew Phillips and Rebecca Lodwick, University College London Medical School, Royal Free Campus, London, UK)

The HIV Indicator Diseases Across Europe Study Group. Advisory Group: N Clumeck, Saint-Pierre University Hospital, Brussels, Belgium, J Gatell, Hospital Clínic de Barcelona, Barcelona, Spain, B Gazzard, Chelsea and Westminster Hospital, London, England, J Lundgren, University of Copenhagen and Rigshospitalet, Copenhagen, Denmark, A d’Arminio Monforte, Unit of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy, J Rockstroh, Department of Medicine, University of Bonn, Germany, A Mocroft, University College London Medical School, UK, Y Yazdanpanah, Hopital Bichat Claude Bernard, Paris, France. **Centres:** **Austria:** R Zangerle, M Kitchen, University Hospital Innsbruck, Department of Dermatology and Venereology, Innsbruck.

Belarus: A Vassilenko, Minsk Municipal Infectious Diseases Hospital, Minsk. **VM Mitsura, Gomel State Medical University, Gomel.** **Belgium:** C Necsoi, P Kirkove, Saint-Pierre University Hospital, Brussels. **Bosnia:** V Hadziosmanovic, Clinical Center, University of Sarajevo, Infectious Diseases Clinic, Sarajevo. **Croatia:** J Begovac, University Hospital of Infectious Diseases, Zagreb. **Denmark:** C Pedersen, Henrik Frederiksen, Iorn Hegelund, Odense Universitetshospital, Ulrik Bak Dragsted, Roskilde Sygehus. **France:** Y Yazdanpanah, Hopital Bichat Claude Bernard, Paris. **Georgia:** N Chkhartishvili, Infectious Diseases, AIDS and Clinical Immunology Centre, Tbilisi, Georgia. **Germany:** U Spengler, Outpatient Clinic for Hepatology, Department of Medicine, University of Bonn. I Schmidt-Wolf, Outpatient Clinic for Hepatology Department of Medicine, University of Bonn. **Greece:** H Sambatakou, Ippokraton General Hospital, Athens. **Israel:** Z M Sthoeger, Ben Ari Institute of Clinical Immunology, Rehovot. **Italy:** A d’Arminio Monforte, T Bini, Unit of Infectious Diseases, San Paolo Hospital, Milan, M Celesia, U.O. Mallattie Infettive Università di Catania, Catania, Sicily, G Orofino, Amedeo di Savoia Hospital, Torino. **Latvia:** P Aldins, Infectology Center of Latvia, Riga. **Netherlands:** K Brinkman, Onze Lieve Vrouwe Gasthuis, Internal Medicine, Amsterdam. **Poland:** A Grzeszczuk, Medical University of Białystok, Department of Infectious Diseases and Hepatology, Białystok. A Horban, Wojewodzki Szpital Zakazny, Warszawa. **Portugal:** F Maltez, Hospital Curry Cabral, Lisbon. **Spain:** M A Goenaga Sánchez, Hospital Donostia, San Sebastian, Spain, A Castro, Hospital Juan Canalejo, Coruña, V P Estrada, Hospital Universitario San Carlos, Madrid, E Ortega Gonzalez, Consorcio Hospital General Univ de Valencia, Valencia, A Ocampo, Complejo Xeral Cies de Vigo, Vigo, M Masiá, Hospital Universitario de Elche, Elche, F Garcia, A Leon, Hospital Clínic Barcelona, Infectious Diseases Unit, Barcelona. I Menacho, Primary Center of les Corts, M Muns, Primary Center of Raval Sur, Barcelona, C Agustí, CEEISCAT, Barcelona. Spain. **Sweden:** A Sönnberg, Department of Infectious Diseases, Karolinska University Hospital, Stockholm. **Switzerland:** P Vernazza, Kantonsspital, St Gallen. **United Kingdom:** A Sullivan, M Rayment, Chelsea and Westminster Hospital, London, S Morris, Western General Hospital, Edinburgh, M Fisher, Royal Sussex Country Hospital, Brighton, A Winston, St. Mary’s Hospital, London, M Tenant-Flowers, London, J Anderson, Homerton University Hospital, London, A Palfreeman, Leicester, J Minton, St James’s University Hospital, Leeds, M Farazmand, Huddersfield Royal Infirmary, West Yorkshire, ELC Ong, The Newcastle upon Tyne Hospital, Newcastle, UK. **Ukraine:** G Kutsyna, Luhansk AIDS Center, Luhansk, A Kuznetsova, Kharkov Regional Clinic of Infectious Diseases, Kharkov. **Coordinating Centre Staff:** D Raben, ML Jakobsen, G Nanfuka, F Marcher, R S Brandt. **Statistical Analysis:** A Mocroft, University College London, UK

Panel on Guidance on Indicator Condition-Guided HIV testing in Adults: European Centre for Disease Prevention and Control, Sweden, represented by Marita van de Laar; WHO Europe, Denmark, represented by Lali Khotenashvili; Nathan Clumeck, CHU Saint-Pierre, Brussels, Belgium; Jose Gatell, Hospital Clínic – IDIBAPS, University of Barcelona, Spain; Brian Gazzard, Chelsea and Westminster Hospital, London, UK; Jens Lundgren, University of Copenhagen and Rigshospitalet, Copenhagen; Antonella d’Arminio Monforte, Infectious Diseases Unit, San Paolo University Hospital, Milan, Italy; Jürgen Rockstroh, Medizinischen Universitätsklinik, Bonn, Germany; Amanda Mocroft, University College London, UK; Ann Sullivan, Chelsea and Westminster Hospital, London, UK; Valerie Delpech, Health Protection Agency, UK; Martin Fisher, Royal Sussex County Hospital, Brighton, UK; Francesco Blasi, Alberto Mateelli, European Respiratory Society (ERS); Gabriele Arendt, Universitätsklinikum Neurologische Klinik Düsseldorf, Germany, European Neurological Society (ENS); Keith Radcliffe, European branch of the International Union against Sexually Transmitted Infections (IUSTI), Tallinn, Estonia; Deniz Gokengin, IUSTI Europe, Turkey; José Miro, Hospital Clínic IDIBAPS, University of Barcelona, Barcelona, Spain; Bruno Hoen, Centre Hospitalier Universitaire Hôpital Saint Jacques de Maladies Infectieuses et Tropicales, Besancon, France, on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Erwin Tschachler, European Academy of Dermatology and Venereology (EADV); Anne-Françoise Gennotte, GP, Brussels VCT Center, Brussels; Mika Salminen, National Institute of Health and Welfare (THL), Helsinki, Finland (previously European Centre for Disease Prevention and Control).

The people living with HIV Stigma Index Advisory Group: Wojciech Tomczewski on behalf of ECIUQ (the Eastern European Network for People living with HIV), Henrik Arildsen on behalf of HIV



HIV in Europe
Working Together for Optimal
Testing and Earlier Care



To identify political,
structural, clinical and
social barriers to achieving
optimal testing and care



You are here:- Copenhagen 2012 Conference

Login | Register

- Home
- About
- Copenhagen 2012 Conference
- Project1:Late presentation
- Project2:Infected not yet diagnosed
- Project3:HIDES
- Project4:Stigma Index
- Call to Action 2010-2011
- Conferences
- HIV in Europe Resources
- National Initiatives
- EU and outside Europe
- Other Resources
- Relevant links

Copenhagen 2012 Conference



HIV in Europe
Working Together for Optimal
Testing and Earlier Care
Copenhagen 2012 Conference

NEWS

[Presentations from the HIV in Europe Copenhagen 2012 Conference are now posted at the website](#)



The conference has received funding from the European Commission under the Health Programme 2008-2013. However, the sole responsibility for the study lies with the author

News

HIV 2012 Spain Wednesday, May 16, 2012

HIV 2012 Spain will be held in Madrid on May 29 2012.

[Programme HIV 2012 Spain](#)

Press release 15 March 2012 Thursday, March 15, 2012

"The HIV epidemic in Eastern Europe is out of control and entering into care late is fuelling and HIV/TB epidemic"

[released 15 March 2012 - English](#)
[released 15 March 2012 - Danish](#)

Press release Thursday 1 March, 2012

Friday, March 02, 2012
HIV in Europe Copenhagen 2012 Conference

[Press release "New Indicator Disease reveal hidden HIV"](#)

European Parliament Resolution, December 2011
Wednesday, December 14, 2011